Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ)

• Company Description    X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States. Number of Employees: 143

• Price / Volume Information    Yesterday's Closing Price: $3.26 Daily Weekly Monthly 20 Day Moving Average: 1,640,721 shares Shares Outstanding: 11.41 (millions) Market Capitalization: $37.19 (millions) Beta: 0.61 52 Week High: $26.83 52 Week Low: $1.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.82% 2.00% 12 Week 15.60% 5.01% Year To Date -85.20% -86.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 61 North Beacon Street 4th Floor - Boston,MA 02134 USA ph: 857-529-8300 fax: - daniel@lifesciadvisors.com http://www.x4pharma.com

• General Corporate Information    Officers Paula Ragan - President and Chief Executive Officer Michael S. Wyzga - Chairman Adam S. Mostafa - Chief Financial Officer and Treasurer William E. Aliski - Director Gary J. Bridger - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98420X202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 11.41 Most Recent Split Date: 4.00 (0.03:1) Beta: 0.61 Market Capitalization: $37.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.87 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.53 Price/Cash Flow: - Price / Sales: 1.13 EPS Growth vs. Year Ago Period: -65.07% vs. Previous Quarter: -8,775.00% Sales Growth vs. Year Ago Period: 250.44% vs. Previous Quarter: -93.15% ROE 06/30/25 - -375.31 03/31/25 - -181.56 12/31/24 - -321.45 ROA 06/30/25 - -72.87 03/31/25 - -54.36 12/31/24 - -88.01 Current Ratio 06/30/25 - 3.19 03/31/25 - 3.70 12/31/24 - 3.41 Quick Ratio 06/30/25 - 3.05 03/31/25 - 3.58 12/31/24 - 3.33 Operating Margin 06/30/25 - -311.15 03/31/25 - -288.23 12/31/24 - - Net Margin 06/30/25 - -311.15 03/31/25 - 46.54 12/31/24 - - Pre-Tax Margin 06/30/25 - -310.10 03/31/25 - 47.58 12/31/24 - -1,452.48 Book Value 06/30/25 - 0.50 03/31/25 - 3.96 12/31/24 - 3.90 Inventory Turnover 06/30/25 - 1.93 03/31/25 - 2.40 12/31/24 - 0.52 Debt-to-Equity 06/30/25 - 19.10 03/31/25 - 3.30 12/31/24 - 3.41 Debt-to-Capital 06/30/25 - 95.03 03/31/25 - 76.72 12/31/24 - 77.30

Powered by Zacks Investment Research ©